key: cord-0757507-maa43hpn
authors: Paiva, Kimberly J; Grisson, Ricky D; Chan, Philip A; Lonks, John R.; King, Ewa; Huard, Richard C; Pytel-Parenteau, Diane L; Nam, Ga Hie; Yakirevich, Evgeny; Lu, Shaolei
title: Validation and Performance Comparison of Three SARS-CoV-2 Antibody Assays
date: 2020-05-30
journal: bioRxiv
DOI: 10.1101/2020.05.29.124776
sha: dbba8ff58758e850342b259c092ba50c56a3c199
doc_id: 757507
cord_uid: maa43hpn

Serology testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is increasingly being used during the current pandemic of Coronavirus Disease 2019 (COVID-19). The clinical and epidemiologic utilities of antibody-based SARS-CoV-2 testing are under debate. Characterizing these assays helps to understand the disease and provides scientific basis for deciding how to best use these assays. The study assessed one chemiluminescent assay (Abbott COVID-2 IgG) and two lateral flow assays (STANDARD Q [SQ] IgM/IgG Duo and Wondfo Total Antibody Test). Validation included 113 blood samples from 71 PCR-confirmed COVID-19 patients and 1182 samples from negative controls with potential interferences/cross-reactions, including 1063 pre-pandemic samples. IgM antibodies against SARS-CoV-2 were detected as early as post-symptom onset days 3-4. IgG antibodies were first detected post-onset days 5-6 by SQ assays. The detection rates increased gradually, and SQ IgG, Abbott IgG and Wondfo Total detected antibodies from all the PCR-confirmed patients 14 days after symptom onset. Overall agreements between SQ IgM/IgG and Wondfo Total was 88.5% and between SQ IgG and Abbott IgG was 94.6% (Kappa = 0.75, 0.89). No cross-reaction with other endemic coronavirus infections were identified. Viral hepatitis and autoimmune samples were the main cross-reactions observed. However, the interferences/cross-reactions were low. The specificities were 100% for SQ IgG and Wondfo Total and 99.62% for Abbott IgG and 98.87% for SQ IgM. These findings demonstrate high sensitivity and specificity of appropriately validated antibody-based SARS-CoV-2 assays with implications for clinical use and epidemiological seroprevalence studies.

There is an ongoing worldwide pandemic caused by a novel coronavirus, now known as 42 SARS-CoV-2. The virus was first reported in Wuhan, Hubei Province of China in 2019. 43

Coronavirus Disease 2019 , the disease caused by SARS-CoV-2, has greatly impacted 44 many countries, most especially the United States. There are currently over 5 million confirmed 45 cases worldwide, with over 1.6 million patients in the United States 46 (https://coronavirus.jhu.edu/map.html). Evaluating the spread and transmission of SARS-Cov-2 47 is critical in addressing the pandemic. 48

Development of diagnostic methods for COVID-19 started with SARS-CoV-2 viral 49 genome sequencing first shared by a group of Chinese scientists (1). Real-time reverse 50 transcriptase-polymerase chain reaction (rRT-PCR) based methods have been the mainstay as a 51 diagnostic approach. Most tests use the nasopharyngeal and/or oropharyngeal swabs to obtain 52 the virus before running rRT-PCR. However, it was quickly discovered that the detection rates of 53 pharyngeal and nasal swabs were only 32% and 63%, respectively, and their detection rates 54 decreased as the disease progressed (2). First-time positive rate by pharyngeal swab rRT-PCR 55 was reported as low as 37% in 610 hospitalized patients (3). 56

While rRT-PCR-based testing is the main tool for clinical diagnosis, antibody-based 57 testing has gained considerable attention. Studies suggested that IgM antibody might develop 58 as early as five days after onset of symptoms (4) and IgG developed later at a median time of 14 59 days (4, 5). The sensitivities of these tests reportedly varies widely from as low as 11% early in 60 infection (6) to as high as 100% after 14 days (5). It has been shown that diagnosis of COVID-19 other pathogens were used to test cross-reaction of the assays (Table3). Additional samples 92

were collected consisting of interference antibodies such as Rheumatoid factor (RF), anti-93 double strand DNA (ds-DNA), anti-nuclear antibody (ANA) and paraprotein IgM and IgG (Table  94 3 Of all the 113 samples available from the 71 patients, 105 samples were selected to 100 evaluate antibody positive rates every two days (1-2, 3-4, 5-6, 7-8, 9-10, 11-12, 13-14, and ≥ 15 101 Seroconversion date was defined as the middle point between the date of the last negative and 103 the date of the first positive in one patient. 104

To obtain more precise specificities for SQ IgM, SQ IgG and Abbott IgG, 1063 serum or 105 plasma samples were collected before the pandemic started in the United States (January 106 2020), including 500 samples originally for reference range determination of a troponin assay, 107 371 prenatal samples for reference range determination of quadruple tests, 50 pre-pandemic 108 samples from transfusion service and 21 pre-pandemic plasma segments from the Rhode Island 109

Not all the samples were available for all four tests. Case numbers in the tables and 111

figures may have small difference (up to 4); however, the results and conclusions were not 112 compromised. 113

Lateral flow assays 115 SARS-CoV-2 Total Antibody Test (Wondfo, Guangzhou, China) and STANDARD Q COVID-116 19 IgM/IgG Duo Test kits (SD Biosensor, Gyeonggi-do, Korea) were purchased from the 117 manufacturers and the assays were performed following the manufacturer's protocols (8, 9) . 118

Briefly, 10 µl of serum or plasma was applied to the designated area of the lateral flow strip 119 following three drops of buffer. Positive result was indicated by a visible band in the designated 120 area accompanied with an appropriate control band. Over 90% of the reading was performed 121 by one investigator (K.J.P.) to ensure consistency. 122 SARS-CoV-2 IgG test reagents were purchased from the manufacturer (Abbott 125

Diagnostics, Lake Forest, IL). The assays were performed on an Abbott Architect i1000 analyzer 126 following the manufacturer's protocol. The assay was calibrated initially and with any 127 subsequent reagent lot. A positive and negative Control was run at the start of each batch of 128 antibody testing per manufacturers protocol (10). Serum and plasma samples were both 129 accepted by the assay. Samples with signal-to-cutoff (S/CO) ratio greater than or equal to 1.4 130 were considered positive. 131 132

The data collected were analyzed on a statistical package, JMP Pro 14.0 (SAS Institute, 134

Cary, NC). Categorical data were analyzed via Chi-square analysis or Fisher's exact test 135 whenever appropriate. Wilcoxon method was used in parametric test. 95% confidence intervals 136 were calculated for the sensitivity and specificity. 137

Clinicopathologic features of COVID-19 patients in the study 139 Table 1 summarizes the clinicopathologic features of 71 PCR-confirmed COVID-19 140 patients in this series, including 42 males and 29 females. Average age of the males was 8.1 141 years younger than that of the females (P=0.0470). About one third (38) of the patients were 142

White or Caucasian and 31% (22) were Hispanic or Latino. Africa Americans consisted of 14% 143 (10) of the patients. There was one Asian patient. Many of the patients were either overweight 144 (30%) or obese (47%). Most of them 48 (68%) lived with family members, 9 (13%) in assisted 145 facilities, 9 (13%) alone, and 5 (7%) were homeless. Forty percent (40%) of them had diabetes. The patients' blood samples were collected on average 11.2 days post-symptom onset 161 (Table 1 ). The samples were grouped every two days within the first 2 weeks starting on the 162 symptom onset day 0, and tested by SQ IgM, SQ IgG, Abbott IgG and Wondfo Total antibody 163 assays. Positive results appeared as early as days 3-4 for SQ IgM, days 5-6 for SQ IgG, days 7-8 164

for Abbott IgG and Wondfo Total. After 14 days, all the samples were positive by SQ IgG, Abbott 165

IgG and Wondfo Total. 166

The time points and test results related to seroconversion are listed in Supplemental 167 Table 1 . Twenty-three events of seroconversion were recorded and summarized in Figure 

The Wondfo Total Antibody test detects IgG and IgM. Either a positive IgM or a positive 177

IgG will give a positive result. SQ IgM/IgG Duo is packaged as two independent lateral flow 178 devices that are used to assay IgM and IgG in parallel, but their combined interpretation 179 provides a result comparable with that of the Wondfo Total Antibody test. Out of 113 samples 180 from PCR-confirmed patients with antibody results available from all 3 tests, 65 (58%) were were positive by Wondfo and negative by SQ IgM and IgG. Seven (6.2%) were negative by 183 Wondfo Total and positive by either of SQ IgM and IgG. The overall agreement was 88.5% and 184 the Kappa value was 0.75. (Table 2 ) 185

Between SQ IgG and Abbott IgG, the overall agreement was 94.6% with a Kappa value of 186 0.89. There were 58 (52%) samples positive by both assays and 48 (43%) negative by both. Five 187 (4.5%) were positive by Abbott IgG and negative by SQ IgG. Of these, 4 were positive by 188 Wondfo Total. One (1%) case was positive by SQ IgG but negative by Abbott IgG and Wondfo 189

Total. (Table 2 ) 190 191

To obtain the specificities of four tests, 126 assumedly negative samples collected from 193

routine clinical immunology samples were tested. All resulted negative except SQ IgM which 194 had three positives. The specificities and 95% confidence intervals of SQ IgG, Abbott IgG and 195

Wondfo Total were 100% (97.0%, 100%) for all three and 97.6% (93.2%, 99.2%) for SQ IgM 196 based on this series. (Table 3 ) 197

To examine the assay's cross-reactivity to other viruses, the study included 21 samples 198 from patients with seasonal coronavirus NL63 (n=11), HKU1 (n=7) and 229E (n=3). The 199 diagnoses of virus infection were based on nucleic acid testing. No patients with past OC43 200 infection were evaluated. Blood samples were collected around the diagnoses and after the 201 diagnoses to ensure enough antibody response to be mounted. Eight samples were collected 202 rhinovirus, enterovirus, respiratory syncytial viruses and adenovirus. All these samples were 205 negative by the four tests. (Table 3) (Table 3 ) 216

Samples with anti-nuclear antibodies and paraproteins of IgG and IgM types were all negative 217 by four tests. (Table 3 ) 218

False positive rates of SQ IgM, SQ IgG, and Abbott IgG in pre-pandemic samples 220

Among the 1063 blood samples from frozen pre-pandemic time, SQ IgM had 6 positives 221 from troponin study samples, 2 from plasma segments, and one from prenatal samples. Abbott 222

IgG had 4 positives from troponin study samples. No false positive was seen from SQ IgG results. 223

The specificities and 95% confidence intervals (in parenthesis) for SQ IgM, SQ IgG and Abbott 224 respectively. (Table 4 ) 226 227

The utility of the COVID-19 serology testing is still subject to debate. As shown in Figure  229 1, antibodies started to be detected 3-4 days after the symptom onset. Antibody titers 230 continued to increase and after 2 weeks antibodies could be detected by all the tests except SQ 231

IgM whose positive rate peaked at 87.5% around day 13-14. High sensitivity of serology testing 232 after 2 weeks of symptom onset was shown in other studies (11, 12) . In one study, 100% 233 sensitivity was seen in Diazyme IgM/IgG assay ≥ 15 days post PCR diagnosis (11) and another 234 study reported 93.8% (95% CI; 82.80-98.69) at ≥14d post symptom onset for Abbott IgG (12). 235

Serology testing could be used as part of the diagnostic panel after 14 days post 236 symptom onset when the positive rates were the highest and the sensitivity of swab PCR 237 decreased (2, 3). At our institution, it is not uncommon to see patients who were highly 238 suspected of COVID-19 based on signs and symptoms have positive antibody tests while rRT-239 PCR tests were repeatedly negative. The seroconversion could be detected during the second 240

week post symptom onset ( Figure 2 ). Presence of a seroconversion in a highly suspicious 241 COVID-19 patient should be diagnostic in the right clinical settings. The utility of the testing 242 before 2 weeks post symptom onset should be best decided on a case-by-case basis. 243

The overall agreement between SQ IgM/IgG and Wondfo Total was as high as 88.5% 244 with Kappa of 0.75. The overall agreement between Abbott IgG and SQ IgG was as high as 94.6% 245 with Kappa of 0.89. The disagreement cases were samples collected during the first 2 weeks of 246 symptoms. Since the tests were generally not recommended before 2 weeks post symptom 247 onset, the difference among the assays would not be clinically significant. 248

It has been widely considered that the SARS-CoV-2 antibodies may be cross-reactive to 251 seasonal coronaviruses, such as NL63, 229E, HKU1, and OC43. The latter two belong to beta 252 subgroup which also includes SARS-CoV-2. The detection of non-COVID coronaviruses varies 253 from year to year and in some years accounted for as much as 22%-25% of adult respiratory 254 illness (13, 14) . Therefore, if cross reactivity did exist, the utility of the SARS-CoV-2 antibody test 255 would be greatly limited. In the current study, among the 21 samples from patients with 256 coronaviruses NL63, HKU1 and 229E, 13 were collected at the time of diagnosis and 8 collected 257

at least 2 weeks after the diagnosis to ensure sufficient development of immune response. All 258 four tests performed well and none of them were reactive to the 21 samples in the study. 259

Consistent with our findings, one study included 5 seasonal coronavirus samples and they were 260 all negative by Abbott IgG (12). Seasonal coronaviruses are known for their short periods of 261 immunity after infection. It is known that antibodies against seasonal coronaviruses reached 262 peak titers in 2 weeks and slowly declined and the protection is largely lost a year later (15); 263 however, due to repeat infection, a report found that adult population had a high 264 seroprevalence of coronaviruses (91.3% for 229E, 59.2% for HKU1, 91.8% for NL63, and 90.8% 265 for OC43) from a United States Metropolitan Population (11). In the current study we included 266 over 1000 samples from pre-pandemic era and overall found very low positive rates in SQ IgM, 267 SQ IgG and Abbott IgG, which echoes the findings from Abbott (10) and an independent study 268 (16) . The Wondfo Total was not tested in this evaluation. Given the high prevalence of 269 coronavirus infection in the general population (11), if the cross-reactions were common, the 270 positive rates would be expected to be higher. when the disease prevalence is low. It is estimated that for an assay with 99% specificity, the 295 positive predictive value is only ~50% in a disease with prevalence of 1%. The SQ IgG and 296

Abbott IgG reached over 99% specificities at the lower ends of their 95% confidence intervals. 297

The SQ IgG was negative in all the 1063 negative cases, with 99.64% specificity at the lower end 298 of its 95% confidence interval. Even with 99.64% specificity, the positive predictive value 299 increases to 74% in a disease with prevalence of 1%, and the positive predictive value increases 300 to 93% in a disease with prevalence of 5%. 301 302

The main limitation of the study is that the samples from COVID-19 patients were 304 collected from an inpatient population. This group of patients were generally overweight or 305 obese (77%) with high prevalence of diabetes (40%). They tended to have a high D-Dimer levels 306

and marked lymphocytopenia. The clinical symptoms tended to be severe with more being 307 intubated and poor clinical outcomes. The antibody response in this population has been 308 shown to be robust (17). In outpatient population, asymptomatic infected individuals have 309 been reported only with ~ 10% (28/276) seropositive rates (20). Moreover, asymptomatic and 310 pauci-symptomatic patients could have no detectable antibody response 4 weeks after the 311 diagnosis (21). Another limitation is the limited number of non-COVID positive samples 312 collected at least 2 weeks post symptom onset. More work is needed to assess these tests in 313 this patient population. 314 will persist. The three samples collected over 30 days post symptom onset had Abbott S/CO 316 reading of 7.58 (31 days), 6.37 (31 days) and 2.43 (35 days). The last one was from a patient 317 with end stage renal disease which is known for its attenuated immune response. The other 318 two were among the most robust immune responses in this cohort (both over 90% quantile of 319 S/CO readings). Obviously, follow-up testing of these patients' antibody S/CO levels will help to 320 answer the question. 321

In summary, we validated three SARS-CoV-2 antibody tests, including two lateral flow 322 assays (Wondfo Total Antibody and SQ IgM/IgG combo) and one chemiluminescent assay 323 (Abbott IgG). All tests except SQ IgM performed well with excellent sensitivities two weeks after 324 symptom onset and excellent overall specificities. Hepatitis and autoimmune samples were the 325 main sources of very low interferences/cross-reactions. 0/11 0/7 0/3 0/4 0/6 0/1 0/2 0/4 0/5 0/2 0/1 0/2 0/4 1/5 n 1/1 o 0/2 0/4 0/5 0/5 0/1 0/1 0/3 0/5 0/6 0/1 0/5 1/3 s 0/5 0/5 0/5 0/4 3/118 0/10 0/6 0/3 0/4 0/6 0/1 0/2 0/4 0/5 0/2 0/1 0/2 0/4 0/5 0/1 0/2 0/4 0/5 0/5 1/1 p 0/1 1/3 p 0/5 0/6 0/1 0/5 0/3 0/5 0/5 0/5 0/4 2/116 0/11 0/7 0/3 0/4 0/6 0/1 0/2 0/4 0/5 0/2 0/1 0/2 0/4 0/5 0/1 0/2 0/4 0/5 0/5 0/1 0/1 1/3 p 1/5 q 0/6 0/1 0/5 1/3 s 1/5 t 0/5 0/5 0/4 4/118 0/11 0/7 0/3 0/4 0/6 0/1 0/2 0/4 0/5 0/2 0/1 0/2 0/5 0/5 0/1 0/2 0/4 0/5 0/5 0/1 0/1 0/3 0/5 0/6 1/1 r 0/5 0/3 0/5 0/5 0/5 0/4 1/119 a: Two of the three cases was followed up clinically (44 and 61 days after blood collection). COVID-19 was not 443 developed. Mean ± SEM* 7.9 ± 0.7 7.6 ± 0.5 7.6 ± 0.7 8.1 ± 0.5

Range 5.5 -11 5.5 -10 5.5 -10.5 5.5 -11 0 2 4 6 8 10 12 days *P = 0.9365

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG 384

2020 Test performance evaluation of SARS-CoV-2 394 serological assays medRxiv

Emergence of a Novel Coronavirus

Protocol for Extending Surveillance Used by the Royal College of General Practitioners 400 Research and Surveillance Centre and Public Health England

454 l: blood collected 38 days post PCR diagnosis 455 m: blood collected 0 and 23 days post PCR diagnosis 456 n: No COVID-19 was developed on the positive case at 20 days follow-up. 457 o: No COVID-19 was developed on the positive case at 21 days follow-up. 458 p: No follow-up was available on the positive case 459 q: No COVID-19 was developed on the positive case at 38 days follow-up. 460 r: No COVID-19 was developed on the positive case at 17 days follow-up. 461 s: No COVID-19 was developed on the positive case at 18 days follow-up